Abstract
The nuclear factor kappaB (NF-κB) is a family of transcription factors that control cell survival, cell proliferation, cell differentiation, inflammatory responses, and innate and adaptive immune responses. Its activation is tightly regulated, and incorrect regulation of NF-κB has been linked to a variety of pathological diseases, including cancer initiation and progression. NF-κB is often constitutively activated in cancer cells to promote cell survival, proliferation, migration, and/or epithelial-to-mesenchymal transition (EMT). Although the mechanism of constitutive NF-κB activation in cancer cells is not fully understood, it has been shown that mutation or aberrant expression of epidermal growth factor receptor (EGFR) contributes to this, and the NF-κB activation, in turn, contributes to cell proliferation, survival, metastasis, and drug resistance in various cancers. Recent study from our lab indicates that CARMA3, similar to the function of CARMA1 in mediating antigen receptor-mediated NF-κB activation, plays an essential role in mediating EGFR-induced NF-κB activation. However, the mechanism on how EGFR induces NF-κB activation is not clearly understood. In this chapter, we describe the methods required to test and characterize the role of a potential signaling component in EGFR-induced NF-κB activation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18(18):2195–2224
Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621–663
Baud V, Jacque E (2008) The alternative NF-kB activation pathway and cancer: friend or foe? Med Sci (Paris) 24(12):1083–1088
Dolcet X et al (2005) NF-kB in development and progression of human cancer. Virchows Arch 446(5):475–482
Feinman R, Siegel DS, Berenson J (2004) Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol 2(3):162–166
Giuliani C et al (2001) Nf-kB transcription factor: role in the pathogenesis of inflammatory, autoimmune, and neoplastic diseases and therapy implications. Clin Ter 152(4):249–253
Ivanenkov YA, Balakin KV, Lavrovsky Y (2011) Small molecule inhibitors of NF-kB and JAK/STAT signal transduction pathways as promising anti-inflammatory therapeutics. Mini Rev Med Chem 11(1):55–78
Salminen A et al (2008) Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev 7(2):83–105
Hideshima T et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277(19):16639–16647
Biswas DK et al (2003) Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Res 63(2):290–295
Biswas DK et al (2005) Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE 2005(288):pe27
Wang Z et al (2006) Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res 66(15):7653–7660
Ando K et al (2005) Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res 11(24 Pt 1):8872–8879
Le Page C et al (2005) EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 65(2):130–140
Shimizu M et al (2005) Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 11(7):2735–2746
Marciniak DJ et al (2004) Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. Mol Cancer Ther 3(12):1615–1621
Wang H et al (2004) Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84(8):941–951
Thornburg NJ, Pathmanathan R, Raab-Traub N (2003) Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 63(23):8293–8301
Bancroft CC et al (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99(4):538–548
Bhat-Nakshatri P, Sweeney CJ, Nakshatri H (2002) Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 21(13):2066–2078
Pianetti S et al (2001) Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20(11):1287–1299
Remon J et al (2014) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev 40(1):93–101
Matusan-Ilijas K et al (2013) EGFR expression is linked to osteopontin and Nf-kappaB signaling in clear cell renal cell carcinoma. Clin Transl Oncol 15(1):65–71
Biswas DK, Iglehart JD (2006) Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 209(3):645–652
Biswas DK et al (2000) Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97(15):8542–8547
Ahmed KM, Cao N, Li JJ (2006) HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res 26(6B):4235–4243
Blonska M, Lin X (2011) NF-kappaB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 21(1):55–70
Medoff BD et al (2009) CARMA3 mediates lysophosphatidic acid-stimulated cytokine secretion by bronchial epithelial cells. Am J Respir Cell Mol Biol 40(3):286–294
Mahanivong C et al (2008) Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 27(9):1273–1280
Jiang C, Lin X (2012) Regulation of NF-kappaB by the CARD proteins. Immunol Rev 246(1):141–153
Jiang T et al (2011) CARMA3 is crucial for EGFR-induced activation of NF-{kappa}B and tumor progression. Cancer Res 71(6):2183–2192
Marsigliante S, Vetrugno C, Muscella A (2013) CCL20 induces migration and proliferation on breast epithelial cells. J Cell Physiol 228(9):1873–1883
Grabiner BC et al (2007) CARMA3 deficiency abrogrates G-protein-coupled receptor-induced NF-kappaB activation. Genes Dev 21(8):984–986
Acknowledgments
This work was partially supported by grants from the National Institutes of Health (GM065899 and GM079451) and from the Cancer Prevention Research Institute of Texas (RP120316) to X. Lin.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Jiang, C., Lin, X. (2015). Analysis of Epidermal Growth Factor-Induced NF-κB Signaling. In: May, M. (eds) NF-kappa B. Methods in Molecular Biology, vol 1280. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2422-6_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2422-6_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2421-9
Online ISBN: 978-1-4939-2422-6
eBook Packages: Springer Protocols